Lantern Pharma (NASDAQ:LTRN) Director D Jeffrey Keyser Acquires 48,544 Shares of Stock

Lantern Pharma Inc. (NASDAQ:LTRN) Director D Jeffrey Keyser acquired 48,544 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were bought at an average price of $2.06 per share, with a total value of $100,000.64. Following the completion of the transaction, the director directly owned 94,303 shares of the company’s stock, valued at approximately $194,264.18. The trade was a 106.09% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Lantern Pharma Stock Up 24.7%

Shares of LTRN stock opened at $3.13 on Friday. The firm has a 50 day moving average price of $2.22 and a two-hundred day moving average price of $2.92. The company has a market capitalization of $35.40 million, a PE ratio of -1.99 and a beta of 2.10. Lantern Pharma Inc. has a 12-month low of $1.11 and a 12-month high of $5.74.

Lantern Pharma (NASDAQ:LTRN) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.10.

Wall Street Analyst Weigh In

LTRN has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Lantern Pharma to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lantern Pharma currently has an average rating of “Sell”.

Institutional Investors Weigh In On Lantern Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Lantern Pharma by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after buying an additional 4,661 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Lantern Pharma by 5.1% in the first quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after buying an additional 5,600 shares in the last quarter. Cetera Investment Advisers bought a new position in Lantern Pharma in the fourth quarter valued at approximately $37,000. XTX Topco Ltd bought a new position in Lantern Pharma in the second quarter valued at approximately $40,000. Finally, CIBC Private Wealth Group LLC bought a new position in Lantern Pharma in the fourth quarter valued at approximately $47,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.